olaparib
astrazeneca,merck
['propel', 'brca']
#esmo22 thought provoking discussion by on the data from propel trial how super-responding brca2 homdels could have been missed in plasma and tissue testing. 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E